用于非小细胞肺癌的中药：疗法与作用机制
Traditional Chinese medicines for non-small cell lung cancer: Therapies and mechanisms.
作者信息
Kong Fanming, Wang Chaoran, Zhao Linlin, Liao Dongying, Wang Xiaoqun, Sun Binxu, Yang Peiying, Jia Yingjie
机构信息
Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China.
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China.
出版信息
Chin Herb Med. 2023 Sep 21;15(4):509-515. doi: 10.1016/j.chmed.2023.05.004. eCollection 2023 Oct.
Abstract
The most common subtype of lung cancer is non-small cell lung cancer (NSCLC), which has a poor prognosis and seriously threatens the health of human beings. The multidisciplinary comprehensive treatment model has gradually become the mainstream of NSCLC treatment. Traditional Chinese medicine (TCM) can be used effectively either as an adjunctive therapy or alone throughout the NSCLC therapy, which has a significant impact on survival, quality of life, and reduction of toxicity. Therefore, this paper reviewed the theoretical basis, the latest clinical application, and combined treatment mechanisms in order to explore the advantage stage of TCM treatment and the synergistic therapeutic mechanisms.
摘要
肺癌最常见的亚型是非小细胞肺癌（NSCLC），其预后较差，严重威胁人类健康。多学科综合治疗模式已逐渐成为NSCLC治疗的主流。在整个NSCLC治疗过程中，中医药既可以作为辅助治疗有效使用，也可以单独使用，这对生存期、生活质量及降低毒性有显著影响。因此，本文回顾了其理论基础、最新临床应用及联合治疗机制，以探讨中医药治疗的优势阶段及协同治疗机制。
相似文献
1
Traditional Chinese medicines for non-small cell lung cancer: Therapies and mechanisms.用于非小细胞肺癌的中药：疗法与作用机制
Chin Herb Med. 2023 Sep 21;15(4):509-515. doi: 10.1016/j.chmed.2023.05.004. eCollection 2023 Oct.
2
Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial.中药治疗作为晚期非小细胞肺癌的维持治疗：一项随机对照试验。
Complement Ther Med. 2016 Feb;24:55-62. doi: 10.1016/j.ctim.2015.12.006. Epub 2015 Dec 17.
3
Astragalus-containing Traditional Chinese Medicine, with and without prescription based on syndrome differentiation, combined with chemotherapy for advanced non-small-cell lung cancer: a systemic review and meta-analysis.含黄芪的中药，无论是否辨证论治开方，联合化疗治疗晚期非小细胞肺癌：一项系统评价和荟萃分析。
Curr Oncol. 2016 Jun;23(3):e188-95. doi: 10.3747/co.23.2920. Epub 2016 Jun 9.
4
Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations.中药延长表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗携带 EGFR 突变的非小细胞肺癌（NSCLC）患者无进展生存期并增强治疗效果。
Med Sci Monit. 2019 Nov 9;25:8430-8437. doi: 10.12659/MSM.917251.
5
6
Comprehensive TCM treatments combined with chemotherapy for advanced non-small cell lung cancer: A randomized, controlled trial.中药联合化疗治疗晚期非小细胞肺癌的随机对照试验。
Medicine (Baltimore). 2021 May 7;100(18):e25690. doi: 10.1097/MD.0000000000025690.
7
Comprehensive geriatric assessment and traditional Chinese medicine intervention benefit symptom control in elderly patients with advanced non-small cell lung cancer.综合老年评估和中医干预有助于晚期非小细胞肺癌老年患者的症状控制。
Med Oncol. 2015 Apr;32(4):114. doi: 10.1007/s12032-015-0563-5. Epub 2015 Mar 15.
8
The positive role of traditional Chinese medicine as an adjunctive therapy for cancer.中医作为癌症辅助治疗手段的积极作用。
Biosci Trends. 2021 Nov 21;15(5):283-298. doi: 10.5582/bst.2021.01318. Epub 2021 Aug 20.
9
The efficacy and safety of Zengxiao Jiandu decoction combined with definitive concurrent chemoradiotherapy for unresectable locally advanced non-small cell lung cancer: a randomized, double-blind, placebo-controlled clinical trial.增消减毒汤联合根治性同步放化疗治疗不可切除局部晚期非小细胞肺癌的疗效与安全性：一项随机、双盲、安慰剂对照临床试验
Ann Transl Med. 2022 Jul;10(14):800. doi: 10.21037/atm-22-2814.
10
Traditional Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer: key drug screening and mechanism analysis.中药联合化疗治疗晚期非小细胞肺癌：关键药物筛选及机制分析
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):843-854. doi: 10.1007/s00210-024-03310-5. Epub 2024 Jul 29.
引用本文的文献
1
Integrating network pharmacology, bioinformatics and molecular docking to explore the anti-NSCLC mechanisms of EGCG in green tea.整合网络药理学、生物信息学和分子对接技术以探究绿茶中表没食子儿茶素没食子酸酯（EGCG）抗非小细胞肺癌（NSCLC）的机制。
Medicine (Baltimore). 2025 Sep 5;104(36):e44070. doi: 10.1097/MD.0000000000044070.
2
Current landscape of innovative drug development and regulatory support in China.中国创新药物研发与监管支持的现状
Signal Transduct Target Ther. 2025 Jul 22;10(1):220. doi: 10.1038/s41392-025-02267-y.
3
Chinese herbal medicine improves the treating outcomes in advanced non-small cell lung cancer patients treated with iodine-125 seed brachytherapy: a 5-year follow-up study.中药改善接受碘-125粒子近距离治疗的晚期非小细胞肺癌患者的治疗效果：一项5年随访研究。
Front Med (Lausanne). 2025 Jun 25;12:1595640. doi: 10.3389/fmed.2025.1595640. eCollection 2025.
4
Nanomedicine initiates ferroptosis for enhanced lung cancer therapy.纳米医学引发铁死亡以增强肺癌治疗效果。
Drug Deliv. 2025 Dec;32(1):2527752. doi: 10.1080/10717544.2025.2527752. Epub 2025 Jul 5.
5
Efficacy and safety of oral Chinese medicine combined with chemotherapy: a systematic review and network meta-analysis.口服中药联合化疗的疗效与安全性：一项系统评价与网状Meta分析
Front Pharmacol. 2025 Jun 12;16:1579613. doi: 10.3389/fphar.2025.1579613. eCollection 2025.
6
Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024.变革者：2024年获美国食品药品监督管理局批准的重磅小分子药物
Pharmaceuticals (Basel). 2025 May 15;18(5):729. doi: 10.3390/ph18050729.
7
Advances in Lung Cancer Treatment: Integrating Immunotherapy and Chinese Herbal Medicines to Enhance Immune Response.肺癌治疗进展：整合免疫疗法与中草药以增强免疫反应
Chin J Integr Med. 2025 May 23. doi: 10.1007/s11655-025-4134-0.
8
Revolutionizing lung cancer treatment: harnessing exosomes as early diagnostic biomarkers, therapeutics and nano-delivery platforms.革新肺癌治疗：利用外泌体作为早期诊断生物标志物、治疗剂和纳米递送平台。
J Nanobiotechnology. 2025 Mar 21;23(1):232. doi: 10.1186/s12951-025-03306-0.
9
Traditional Chinese medicine in lung cancer treatment.中医在肺癌治疗中的应用。
Mol Cancer. 2025 Feb 26;24(1):57. doi: 10.1186/s12943-025-02245-6.
10
Enhancing chemoimmunotherapy for colorectal cancer with paclitaxel and alantolactone via CD44-Targeted nanoparticles: A STAT3 signaling pathway modulation approach.通过靶向CD44的纳米颗粒增强紫杉醇和土木香内酯对结直肠癌的化学免疫治疗：一种STAT3信号通路调节方法。
Asian J Pharm Sci. 2025 Feb;20(1):100993. doi: 10.1016/j.ajps.2024.100993. Epub 2024 Nov 12.
本文引用的文献
1
A Chinese classical prescription Qianjinweijing Decoction in treatment of lung cancer: An overview.千金苇茎汤治疗肺癌的中国古典方：概述。
Biomed Pharmacother. 2022 Dec;156:113913. doi: 10.1016/j.biopha.2022.113913. Epub 2022 Oct 26.
2
Annual report to the nation on the status of cancer, part 1: National cancer statistics.国家癌症报告：癌症统计数据 1. 全国癌症统计数据概览
Cancer. 2022 Dec 15;128(24):4251-4284. doi: 10.1002/cncr.34479. Epub 2022 Oct 27.
3
A Clinical Study on the Use of Yiqi Yangxue Decoction Combined with Chemotherapy to Promote Rapid Postoperative Recovery in Patients with Non-Small Cell Lung Cancer.益气养血汤联合化疗促进非小细胞肺癌患者术后快速康复的临床研究
Emerg Med Int. 2022 Sep 9;2022:7073893. doi: 10.1155/2022/7073893. eCollection 2022.
4
6,6'-Bieckol induces apoptosis and suppresses TGF-β-induced epithelial-mesenchymal transition in non-small lung cancer cells.6,6'-联表儿茶素诱导非小细胞肺癌细胞凋亡并抑制转化生长因子-β诱导的上皮-间质转化。
Chin Herb Med. 2021 Nov 23;14(2):254-262. doi: 10.1016/j.chmed.2021.05.005. eCollection 2022 Apr.
5
Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial.预防性中药对阿法替尼治疗突变阳性晚期肺腺癌皮肤毒性的疗效：一项单中心、前瞻性、双盲、随机对照的初步试验。
Integr Cancer Ther. 2022 Jan-Dec;21:15347354221086663. doi: 10.1177/15347354221086663.
6
Ophiopogonin B alleviates cisplatin resistance of lung cancer cells by inducing Caspase-1/GSDMD dependent pyroptosis.麦冬皂苷B通过诱导半胱天冬酶-1/ Gasdermin D依赖性细胞焦亡减轻肺癌细胞的顺铂耐药性。
J Cancer. 2022 Jan 1;13(2):715-727. doi: 10.7150/jca.66432. eCollection 2022.
7
Comparative efficacy of 10 Chinese herbal injections combined with GP regimen chemotherapy for patients with advanced NSCLC a systematic review and network meta-analysis.10种中药注射剂联合GP方案化疗治疗晚期非小细胞肺癌患者的疗效比较：一项系统评价与网状Meta分析
J Cancer. 2022 Jan 1;13(2):465-480. doi: 10.7150/jca.66410. eCollection 2022.
8
Cancer statistics, 2022.癌症统计数据，2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
9
First-Line Immunotherapy for Non-Small-Cell Lung Cancer.非小细胞肺癌的一线免疫治疗。
J Clin Oncol. 2022 Feb 20;40(6):586-597. doi: 10.1200/JCO.21.01497. Epub 2022 Jan 5.
10
Qing-Kai-Ling Injection Acts Better Than Shen-Fu Injection in Enhancing the Antitumor Effect of Gefitinib in Resistant Non-Small Cell Lung Cancer Models.清开灵注射液在增强吉非替尼对耐药非小细胞肺癌模型的抗肿瘤作用方面比参附注射液效果更好。
Evid Based Complement Alternat Med. 2021 Oct 4;2021:9911935. doi: 10.1155/2021/9911935. eCollection 2021.
Zotero 插件